Example: Heart Attack

Clinical Trials on Glabellar Crease

Total 10000 results

NCT06722612

Recruiting

Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer (TaxCbHER2)

HER2-positive Breast Cancer
NCT06711068

Recruiting

Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy (TaxDHER2)

HER2-positive Breast Cancer
NCT06707584

Not yet recruiting

Role of MRI in Breast Cancer Subtypes (MRI)

MRI in Breast Cancer
NCT06706557

Recruiting

Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer (LEGO)

Advanced Metastatic Breast Cancer
NCT06548178

Not yet recruiting

T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer

HER2-positive Breast Cancer
NCT06517992

Not yet recruiting

Collaborative cOMMUNIty Care for Metastatic breAsT cancEr Patients in inDonesia (Communicated) (Communicated)

Cancer | Metastatic Breast Cancer
NCT06512558

Recruiting

Augmented Reality Feasibility for Non-invasive Preoperative Tracking in Breast Cancer Surgery (AR-GBS)

Subclinical Breast Cancer Lesion
NCT06499168

Not yet recruiting

Predicting Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Locally Advanced Breast Cancer
NCT06361264

Recruiting

Clinical Study of Personalized Chemotherapy for Breast Cancer With Low Doses of Cyclophosphamide

Stage IV Breast Cancer
NCT06330012

Recruiting

The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.

HER2-positive Breast Cancer
NCT06313086

Recruiting

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

HER2-positive Breast Cancer
NCT06236269

Recruiting

HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan (ACROSS-TROP2)

Breast Cancer Stage IV
NCT06143553

Recruiting

Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer

Metastatic Breast Cancer (MBC)
NCT05982626

Recruiting

Study of 68Ga /131I SGMIB-ZT-199 PET Imaging Targeting HER2-positive in the Diagnosis of Metastatic Breast Cancer

HER2-positive Breast Cancer
NCT05945368

Recruiting

A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC

HER2-positive Breast Cancer
NCT05911958

Recruiting

A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

HER2 Low Breast Carcinoma
NCT05889871

Not yet recruiting

A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer

HR+/HER2-breast Cancer
NCT05861271

Recruiting

Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer

Breast Cancer Stage I
NCT05720026

Recruiting

Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer

HER2-positive Breast Cancer
NCT05698186

Not yet recruiting

Thero2-01S22 in HER2-positive Breast Cancer

HER2-positive Breast Cancer
NCT05676866

Not yet recruiting

Evaluation of Targeted Axillary Lymph Node Dissection in Node Positive Breast Cancer Patients Post Neo Adjuvant Therapy

Node-positive Breast Cancer
NCT05670054

Recruiting

Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients

Breast Cancer Stage IV
NCT05635487

Recruiting

A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

HER2-positive Breast Cancer
NCT05633914

Recruiting

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

HR+/HER2- Breast Cancer
NCT05558722

Recruiting

Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer (ACNTBC)

Breast Cancer Stage II
NCT05462457

Recruiting

TAD in Primary Breast Cancer With Initially ≥ 3 Suspicious Lymph Nodes (SenTa2)

Breast Cancer | Node-positive Breast Cancer
NCT05388149

Recruiting

Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease

Breast Cancer | HER2-positive Breast Cancer
NCT05306041

Recruiting

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer (GeparPiPPa)

HER2-positive Breast Cancer
NCT05280288

Not yet recruiting

Effect of the App Bone@BC Version 4.0 Under the Follow-up for Patients With Early Breast Cancer

Early-stage Breast Cancer
NCT05134519

Not yet recruiting

RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer

Breast Cancer | HER2-positive Breast Cancer
NCT04899713

Not yet recruiting

NEOZOL_Follow-up Study (NEOZOL_FU)

Locally Advanced Breast Cancer
NCT04852081

Recruiting

Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

Breast Cancer Stage IV
NCT04469127

Not yet recruiting

A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients. (Heroine01)

Breast Cancer Stage IV
NCT04281641

Recruiting

Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer (PHC-BC)

HER2-positive Breast Cancer
NCT04254263

Recruiting

Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer (ATP)

Locally Advanced Breast Cancer
NCT04170595

Recruiting

Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection

HER2-positive Breast Cancer
NCT04158505

Recruiting

Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer

HER2-positive Breast Cancer
NCT04039893

Recruiting

MUltimodal Targeted Axillary Surgery (MUTAS)

Node-positive Breast Cancer
NCT03461172

Recruiting

Database of Data Collection (BDD-G3S)

Surgery of Breast Cancer
NCT02963363

Recruiting

Adapted Physical Activity for Breast Cancer HER2 Positive Patient (APACAN2)

HER2 Positive Breast Cancer
NCT07068477

Completed

Adaptation of a Values Assessment Tool

Cancer | Metastatic Breast Cancer
NCT05675579

Active, not recruiting

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

Breast Cancer
NCT03513614

Active, not recruiting

Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS) (TAXIS)

Node-positive Breast Cancer
NCT04373031

Active, not recruiting

Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer

Breast Cancer | Breast Neoplasms
NCT03366844

Active, not recruiting

Breast Cancer Study of Preoperative Pembrolizumab + Radiation

Breast Cancer
NCT06650748

Enrolling by invitation

Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer (NeoMARS)

Breast Cancer | Early-stage Breast Cancer
NCT03255577

Active, not recruiting

Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer

Breast Cancer | Locally Advanced Breast Cancer
NCT07416409

Completed

Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer

Breast Neoplasms | Metastatic Breast Cancer | HER2-positive Breast Cancer | Oncology
NCT06068985

Active, not recruiting

Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade (CHERRY-PICK)

Breast Cancer | HER2-positive Breast Cancer
NCT03664687

Completed

Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL) (REaCT-ZOL)

Early-stage Breast Cancer

Clinical Trials on Glabellar Crease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations